Emcure Pharmaceuticals - Success Story of India's 12th Largest Pharmaceutical Company

Shalini Rath Shalini Rath
Jan 6, 2023 8 min read
Emcure Pharmaceuticals - Success Story of India's 12th Largest Pharmaceutical Company

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Emcure Pharmaceuticals.

Imagine a world without quality medicines or treatments. Impossible, right? The industry of pharmaceutical is considered to be the most desired and flourishing industry today. It is responsible for the majority of the country's contribution to the economy.

The business of pharma is a serious one, as they are constantly under the scanner to produce quality medicines. The government does not want to compromise on health, which is why they have to be careful in the way they do their business.

Technology and innovation seem to have been incorporated rightly into these companies allowing them the freedom to develop various medications. These startup companies are in a lucrative area that requires a lot of innovation and continuous research every day to come up with new medicines.

Emcure Pharmaceuticals is an Indian global pharmaceutical company that manufactures tablets, capsules, and injectables.

Let's look at Emcure Pharmaceuticals and its journey to becoming a multinational company. Discover Emcure Pharmaceuticals' founder and team, growth, business model, revenue, competitors, and the challenges faced by them.

Emcure Pharmaceuticals - Company Highlights

Startup Name Emcure Pharmaceuticals
Headquarters Pune, Maharashtra, India
Sector Pharmaceuticals
Founder Satish Ramlal Mehta
Founded 1981
Valuation ₹5000 crore (approx)
Revenue ₹6,091.8 crores (FY21)
Website www.emcure.com

Emcure Pharmaceuticals - About
Emcure Pharmaceuticals - Industry
Emcure Pharmaceuticals - Founder and Team
Emcure Pharmaceuticals - Mission and Vision
Emcure Pharmaceuticals - Name, Tagline, and Logo
Emcure Pharmaceuticals - Business Model
Emcure Pharmaceuticals - Revenue
Emcure Pharmaceuticals - Subsidiaries
Emcure Pharmaceuticals - Awards and Achievements
Emcure Pharmaceuticals - Challenges Faced
Emcure Pharmaceuticals - Competitors
Emcure Pharmaceuticals - Future Plans

Emcure Pharmaceuticals - About

Founded about 42 years ago, in 1981, Emcure Pharmaceuticals is now among the top 12 pharma companies in India that engage in the manufacturing of a variety of pharmaceutical products globally.

With five research and development centres spread across 70 countries, Emcure has a strong presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others.

The company has also taken the initiative to launch 6 biosimilars in the Domestic Market & RoW markets & they are the domestic leader in three biologics.

During the Covid-19 pandemic, the company founded its subsidiary, Gennova, which is creating India's first indigenous mRNA vaccine to combat the virus.

Emcure has around 350+ brands with 14 manufacturing facilities established across the country. The company boasts of cutting-edge technology and API facilities that ensure its supply chain works flexibly to have control over manufacturing.

Emcure Pharmaceuticals - Industry

The pharmaceutical industry in India is the world's 3rd largest by volume and 14th largest in terms of value. Without a doubt, Emcure belongs to the pharmaceutical industry.

According to sources, Indian pharma companies play a key part in the country's foreign trade with attractive avenues and opportunities for investors.

It is also reported that the Indian pharma market contributes 57% of APIs to prequalified list of WHO.

Emcure Pharmaceuticals - Founder and Team

The company was started by Satish Ramanlal Mehta in the year 1981.

Satish Ramanlal Mehta

Satish Mehta - Founder of Emcure Pharmaceuticals
Satish Mehta - Founder of Emcure Pharmaceuticals

Satish Mehta is the founder of Emcure pharmaceuticals and also serves as the CEO and MD of the company. He is a postgraduate in Chemistry from Pune University and has a diploma in management from the IIM, Ahmedabad.

Satish Mehta has strong leadership qualities due to which, his company Emcure has become a well-respected company in the global pharma market in more than 70 countries with its key subsidiaries in the UK, Canada, Singapore, Brazil, and others.

He has also served as a member of the Committee to recommend / frame Rules under the Indian Institutes of Management Act, 2017 – Ministry of HRD (Government of India), Economic & Commercial Consultative Group (ECCG) – NITI Aayog (Government of India), and India-China Bilateral Council – NITI Aayog (Government of India).

In 2016, Satish Mehta was ranked on the Forbes Rich List as the 82nd richest Indian with a net worth of $1.6 billion.

Namita Thapar

Namita Thapar - Executive Director, India Business of Emcure Pharmaceuticals
Namita Thapar - Executive Director, India Business of Emcure Pharmaceuticals

Namita Thapar is the Executive Director of Emcure Pharmaceuticals' India business. She is an MBA graduate from the Fuqua School of Business and a Chartered Accountant from the ICAI.

She joined the company as CFO, and her responsibilities grew over time to include managing the company's largest business unit, its India business. Namita is extremely passionate about improving women’s health in India and is also a great promoter of youth entrepreneurship in India.

Namita Thapar is also an avid investor, and her support for Indian startups can be seen on the show Shark Tank India, where she has served as a prominent shark.

Sunil Mehta

Sunil Mehta - Executive Director, Projects of Emcure Pharmaceuticals
Sunil Mehta - Executive Director, Projects of Emcure Pharmaceuticals

Sunil Mehta is the Executive Director, Projects at Emcure Pharmaceuticals. He is a graduate of Commerce from Pune University and a postgraduate in Business Administration from the Institute of Management Development and Research, Pune.

Sunil also serves on the board of Gennova Biopharmaceuticals Ltd., a prominent subsidiary of Emcure Pharmaceuticals.

Emcure Pharmaceuticals - Mission and Vision

The company's vision is mostly about providing quality healthcare solutions globally through maximum technological and innovative scientific techniques.

Emcure likes to work with integrity, deliver quality and patient-focused results, and has strong teamwork and respect among each other.

Here is what Satish Mehta has to say about the company:

“Since inception, Emcure has focused on introducing differentiated products backed by cutting-edge research & development and innovative manufacturing solutions. We continue to work towards our aim of constantly innovating, partnering with local and multi-national, delivering affordable & high-quality healthcare solutions to people and enabling them to lead healthier lives. It’s our conviction that Science will prevail!”

Emcure Pharmaceuticals Logo
Emcure Pharmaceuticals Logo

Emcure's work speaks through its name which is Effective Medicine for Cure. The company rightly does its work by creating effective medicines that reach every patient and help them lead healthier lives.

The company goes by the tagline, "Success through Innovation".

Emcure Pharmaceuticals - Business Model

Emcure has a presence in 70 countries across the world. The company is mostly engaged in developing, manufacturing, and marketing a broad range of pharmaceutical products across the globe. They have 11,000+ employees with 400+ located in other countries.

In India, Emcure's business continues to play a key role in the market today constituting about 41% of the turnover.

Its main offerings are:

  • Biologics
  • Active Pharmaceutical Ingredients (APIs)
  • Vaccines for Covid-19
  • Formulations

Emcure has a strong presence of 4,600 professional doctors with specialisations that have led the company to dominate the Indian market. Besides this, they have become one of the market leaders in therapy areas.

Emcure has waste management and environment protection systems installed at every manufacturing plant to comply with the laws of the environment. They also perform regular audits to keep updates about their operations to ensure ethical activities and compliance.

Emcure Pharmaceuticals - Revenue

Emcure Pharmaceuticals Financials
Emcure Pharmaceuticals Financials

As the company focuses more on chronic and sub-chronic therapies in India, they mostly get its domestic revenue from these areas, which is about 64.75% of its revenue. The therapeutic areas are gynaecology, cardiac, dermatology, anti-infectives, anti-retroviral, gastrointestinal, respiratory, oncology, cardiovascular, pain and vitamins. In FY21, Emcure Pharmaceuticals' revenue was Rs 6,091.8 crore.

The company also claims that there has been 20% growth over the previous year, and the primary growth was through Domestic and international markets especially RoW (Rest of the world) and Canada.

Emcure Pharmaceuticals - Subsidiaries

Below is the list of Emcure Pharmaceuticals subsidiaries:

  • Gennova Biopharmaceuticals Ltd.
  • Zuventus Healthcare Ltd
  • Emcure Nigeria Limited
  • Emcure Pharmaceuticals Mena FZ-LLC
  • Emcure Pharmaceuticals South Africa (Pty) Limited
  • Emcure Brasil Farmaceutica Ltda
  • Heritage Pharma Holdings Inc. d/b/a Avet Pharmaceuticals Holdings Inc.
  • Emcure Pharma UK Ltd
  • Emcure Pharma Peru S.A.C
  • Emcure Pharma Mexico S.A. DE C.V
  • Marcan Pharmaceuticals Inc
  • Emcure Pharmaceuticals Pty Ltd

Emcure Pharmaceuticals - Funding and Investors

With 20% growth from the previous year, the company is now planning to raise Rs 4,500 - 5,000 crore through IPO.

Private company Bain Capital has a 13.09% stake in the company and will sell 99.5 lakhs, while other shareholders will sell 22 lakh shares.

Emcure Pharmaceuticals - Awards and Achievements

Emcure Pharmaceutical sure knows how to do business, and by producing about 350+ brands under its manufacturing, the company has won many awards.

2018

  • Instgra - Best New Introduction of the Year Silver Award by AWACS (21-50-Chronic & Sub Chronic Category).
  • Orofer XT - Brand of the year award for Marketing Excellence - Gold Award by AWACS.
  • Emluz - Best New Introduction of the Year Gold Award by AWACS.
  • Best Indian Patents Award 2017-18 (Highest Number of granted patents) by Indian Drug Manufacturers Association.
  • National Safety Council – Maharashtra Safety Award – 2018 for Zero Accident.

2019

  • Brand of the year award for Marketing Excellence -Bronze Award by AWACS Orofer-XT.
  • Best API Patents Award 2018-19 (Highest Number of API patents) by the Indian Drug Manufacturers Association.
  • Process Development and Commercialization award 2019 for the development of Tenectase, a 3rd generation thrombolytic glycoprotein for acute ischemic stroke (AIS).
  • DISH-Narayan Meghaji Lokhande Health & Safety Award 2019 – Industrial Best Practices.

2020

  • Pronto Consult Consumer Award - Platinum Impact Award Vylda.

2021

  • Exafib - CIMS Medica Healthcare Excellence Award 2021 – Emerging Brand of the Year (Cardiac Care).
  • CIMS Medica Healthcare Excellence Award 2021 – Most Engaging Scientific Platform from Pharma Company.
  • Pronto Consult Consumer Award –Golden Impact Award Ferium 500 Inj.

Emcure Pharmaceuticals - Challenges Faced

The pharmaceutical sector is expanding by creating opportunities for differentiated product varieties. With the rise in drug usage, there are a lot of other pharma manufacturers which pose a challenge for Emcure Pharmaceuticals.

The constant changes in international pharmaceuticals and the regulations associated with it affect the company because the majority of revenue comes from the global market.

The uncertainties of Covid-19 are also a challenge for the company's covid vaccines which are under process and are likely to affect the trial phase.

A few reports suggest that companies like Supriya Lifesciences, and Vijaya Diagnostic Centre among others are also planning to launch their IPO during the same time and this might affect Emcure.

Emcure Pharmaceuticals - Competitors

As mentioned due to the wide options in the pharmaceutical companies, Emcure Pharmaceuticals has tough competitors that could affect their sales growth.

Emcure Pharmaceutical competes with the following companies:

Emcure Pharmaceuticals - Future Plans

Sticking to their tagline, "Success through innovation", the company's subsidiary, Gennova Biopharmaceuticals, was working on an mRNA vaccine for Covid-19 as of 2021.

The company has huge plans to grow its biosimilars and vaccines.

Here's what the CEO of Emcure has to say,

"In a challenging year, we have posted strong 20% growth in revenues, doing well across businesses and also fulfilling our social responsibility in the ongoing pandemic"


Innovacer Success Story - Founders, Business Model, Revenue Model and More
Innovacer is a leading healthcare startup based in the USA founded by Abhinav Shashank, Kanav Hasija, Sandeep Gupta. Here’s its success story.

FAQs

Who is the founder of Emcure Pharmaceuticals?

Satish Ramanlal Mehta is the founder and CEO of Emcure Pharmaceuticals.

What is the revenue of Emcure Pharmaceuticals?

The revenue of Emcure Pharmaceuticals is Rs 6,091.8 crore in FY21.

What is the valuation of Emcure Pharmaceuticals?

The leading pharma company, Emcure Pharmaceuticals has an estimated valuation of Rs 5000 crores.

Must have tools for startups - Recommended by StartupTalky

Great! Next, complete checkout for full access to StartupTalky.
Welcome back! You've successfully signed in.
You've successfully subscribed to StartupTalky.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.